Andernach, February 20, 2019

EsoCap AG and LTS Lohmann Therapy-Systeme AG announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the upper gastrointestinal tract. This collaboration leverages the collective expertise of a strong partner in the thin film industry with a highly innovative application technology.

“We are particularly pleased to be partnering with LTS, a global leader in the development and manufacture of film technologies for the pharmaceutical industry”, said Isabelle Racamier, EsoCap CEO. “We are committed to working closely with LTS to enter rapidly into a clinical trial in patients suffering from eosinophilic esophagitis. EsoCap technology may be beneficial in at least six indications affecting 370 million patients.”

Under the terms of this cooperation, LTS is working on implementation of its thin film know-how as applied to EsoCap’s unique drug delivery technology for diseases of the upper gastrointestinal tract.

“As a company committed to delivering pharmaceutical solutions based on our thin film technology, we are greatly interested in expanding our technology’s fields of application.”, said Dr. Hanshermann Franke, Senior VP Research and Development at LTS. “We are thrilled by EsoCap’s highly innovative approach in the area of drug delivery to the upper gastrointestinal tract.”

About LTS Lohmann Therapie-Systeme AG
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems, such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS´s commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded and proprietary, LTS-funded projects. LTS maintains its leading position through continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, New Jersey, USA, with a representation in Shanghai, China.

For more information, please visit www.ltslohmann.de.

About EsoCap AG
EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.
EsoCap’s vision is to improve the lives of patients with serious diseases through development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.
Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times, with less than two seconds from the mouth to the stomach.
EsoCap owns a unique drug delivery platform, allowing the topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

Contacts:
Dr. Iris Schnitzler
Marketing LTS AG
iris.schnitzler@ltslohmann.de

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland
isabelle.racamier@esocapbiotech.com